Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
SS-31 technically has FDA approval
Retatrutide is the triple GLP-1/GIP/glucagon agonist producing up to 24% body weight reduction in 48 weeks, surpassing both compounds through three simultaneous metabolic pathways Right now, the evidence clearly favors Tirzepatide over Cagrilintide as a standalone metabolic therapy, but Retatrutide makes this comparison obsolete
Follow-up appointments are scheduled as needed to monitor your progress and address any questions or concerns
For doses of 7.5mg and above, the 1ml reconstitution (10mg/ml) produces cleaner single draws
US$ 20.33
US$ 27.28
US$ 27.19
US$ 25.15
US$ 28.06
